Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH et al. Ann Hematol. 2016 Jul 1. [Epub ahead of print].

Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
Jantunen E et al. Expert Rev Hematol. 2016 Jul 15:1-10. [Epub ahead of print].

Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures.
Sanderson F et al. J Clin Apher. 2016 Jul 21. doi: 10.1002/jca.21485. [Epub ahead of print].

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G et al. Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7.

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Pozzi S et al. Leuk Lymphoma. 2016 Jul 21:1-8. [Epub ahead of print].

Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma.
Lida S et al. Int J Hematol. 2016 Jul 26. [Epub ahead of print].

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV et al. Br J Haematol. 2016 Jul 19. doi: 10.1111/bjh.14263. [Epub ahead of print].

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
Hájek R et al. Leukemia. 2016 Jul 15. doi: 10.1038/leu.2016.176. [Epub ahead of print].

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.
Liu L et al. J Hematol Oncol. 2016 Jul 12;9(1):54. doi: 10.1186/s13045-016-0286-x.

Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma : a meta-analysis of 37 trials.
Zou Y et al. Oncotarget. 2016 Jul 21. doi: 10.18632/oncotarget.10768. [Epub ahead of print].